DDDD.L Share News (DDDD)

4D pharma has announced that its treatments for Irritable Bowel Syndrome (IBS) and Paediatric Crohn's Disease (PCD) are expected to enter clinical studies in the second quarter of 2015. The studies, which will be focused on evaluating safety and tolerability of the products as well as some clinical effects. Blautix, the drug for IBS, and Thetanix, the drug for PCD, both use live bacteria rather than chemical entities or antibodies. Alex Stevenson, 4D's chief scientific officer, said: "The Blautix and Thetanix trials will represent important milestones for the company and a new class of therapeutic, designed to treat the underlying causes of diseases rather than just the symptoms. "In addition, 4D continues to generate a strong pipeline of live biotherapeutics for other important diseases, using its proprietary MicroRx platform."Shares in 4D were up 3.3% to 286.68p by 10:20 on Tuesday.NR